Why is CELC Skyrocketing in Premarket Trading Today? - Tokenist
Tokenistarrow_outwardCelcuity Announces Positive Phase 3 Trial Results - TipRanks
TipRanksarrow_outwardCelcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
Yahoo Financearrow_outwardCelcuity's breast cancer combo hits primary endpoints, teeing up FDA filing
Fierce Biotecharrow_outwardCelcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
The Manila Timesarrow_outwardCelcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - TradingView
TradingViewarrow_outwardRelative strength of Celcuity Inc. in sector analysis - Free Earnings Play Trade Plan With Alerts - Newser
Newserarrow_outwardCelcuity stock soars after breakthrough breast cancer drug trial results By Investing.com - Investing.com Nigeria
Investing.com Nigeriaarrow_outwardCelcuity reports breakthrough breast cancer treatment results By Investing.com - Investing.com India
Investing.com Indiaarrow_outwardBreakthrough: New Breast Cancer Drug Quadruples Survival Time in Phase 3 Trial, Sets Historic Efficacy Record - Stock Titan
Stock Titanarrow_outwardCelcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche - Endpoints News
Endpoints Newsarrow_outwardWhy Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Benzingaarrow_outwardWhy Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - inkl
Inklarrow_outwardCelcuity to announce phase 3 VIKTORIA-1 trial results on Monday - Investing.com
Investing.comarrow_outwardCelcuity stock jumps ahead of pivotal breast cancer trial results - Investing.com Australia
Investing.com Australiaarrow_outwardCelcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer - GlobeNewswire
GlobeNewswirearrow_outwardWhat analysts say about Celcuity Inc. stock - Exceptional gains - jammulinksnews.com
Jammulinksnews.comarrow_outwardCelcuity Inc. Stock Analysis and Forecast - Explosive returns - Autocar Professional
Autocar Professionalarrow_outwardCelcuity receives U.S. patent for gedatolisib dosing regimen By Investing.com - Investing.com South Africa
Investing.com South Africaarrow_outwardCelcuity Soars 17.16% on New Patent for Breast Cancer Drug - AInvest
AInvestarrow_outwardCelcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market - MSN
MSNarrow_outwardStifel Assumes Celcuity (CELC) at Buy - StreetInsider
StreetInsiderarrow_outwardCelcuity Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:CELC) - Seeking Alpha
Seeking Alphaarrow_outwardCelcuity Inc. Announces $50 Million Private Placement - ACCESS Newswire
ACCESS Newswirearrow_outwardCelcuity (CELC) Holds a Potential Game-changer in Cancer Treatment - Nasdaq
Nasdaqarrow_outwardCelcuity secures FDA 'breakthrough therapy designation' for breast cancer drug - Star Tribune
Star Tribunearrow_outwardFDA Weekly Review: Avadel, Eton, Pfizer, Celcuity and Others - BioSpace
BioSpacearrow_outwardCelcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer - Business Wire
Business Wirearrow_outwardDavid Dalvey - Twin Cities Business
Twin Cities Businessarrow_outward
Celcuity close
- 2025-07-28 19:50 event
- 29 sourceslanguage
- 100+ ads_click
- 3 weeks ago schedule